← All organizations
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2011Last known activity
Jan 31, 2025
Acquired by Roche on Jan 1, 2015
Timeline
2010s
- Jan 1, 2010
Foundation Medicine— Founded
- Jan 1, 2015
Roche— Acquired By
2020s
- Jun 12, 2020
Lexent Bio— Acquired
Drugs by trial phase (39 distinct, 19 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 2 (28 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Carcinoma
- Carcinoma, Endometrioid
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Cystadenocarcinoma, Serous
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Hypersensitivity
- Neoplasms, Unknown Primary
- Neuroblastoma
- Ovarian Neoplasms
- Peritoneal Neoplasms
- Prostatic Neoplasms
- Urinary Bladder Neoplasms
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (19)
- NCT06745882CollaboratorPhase 2Jan 31, 2025
- NCT05457257CollaboratorPhase 4Jul 29, 2022
- NCT05197322CollaboratorPhase 2Jul 20, 2022
- NCT05062889CollaboratorPhase 2Dec 31, 2021
- NCT04849364CollaboratorPhase 2Aug 24, 2021
- NCT04486352CollaboratorPhase 1/Phase 2Sep 30, 2020
- NCT03824704CollaboratorPhase 2May 15, 2019
- NCT03498521CollaboratorPhase 2Jul 10, 2018
- NCT03397394CollaboratorPhase 2Jun 1, 2018
- NCT03522246CollaboratorPhase 3May 14, 2018
- NCT03462212CollaboratorPhase 1/Phase 2Feb 20, 2018
- NCT02975934CollaboratorPhase 3Jan 1, 2017
- NCT02952534CollaboratorPhase 2Nov 1, 2016
- NCT02795156CollaboratorPhase 2Sep 28, 2016
- NCT02855944CollaboratorPhase 3Sep 1, 2016
Details
- Founded
- Cambridge, MA, US Jan 1, 2010
- Last known activity
- Jan 31, 2025